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Probiotics can prevent necrotizing enterocolitis (NEC) in preterm in‐
fants, reducing the incidence by nearly half in meta‐analysis of trials 
including over 10 000 infants.1 Still, probiotic use is not generally ad‐
opted in all neonatal intensive care units (NICUs), varying from 14% 
in the United States to 58% in Germany.2,3 Why is a cost‐effective 
therapy not generally adopted by all neonatal centres worldwide? 
First, evidence is still lacking in the most optimal treatment strategy 
regarding the strains and dose.4 Second, availability of products ac‐
tually tested for efficacy in clinical trials is limited. Third, reporting of 
safety data is often lacking or inadequate.5 One concern is the risk of 
probiotic sepsis, which has been reported in several preterm infant 
cases.6 However, this complication seems to be very rare, not always 
corresponds to the probiotics in the product, and occurs mainly in 
infants with additional risk factors compromising gut integrity or in 
association with congenital anomalies.3,7‐9 On the other hand, probi‐
otic bacteriaemia may have been overlooked in other cases, because 
anaerobic strains can be difficult to culture from standard single 
paediatric culture bottles. Fourth, there may be local regulatory is‐
sues on a complex product being marketed as either a drug or a food 
additive with or without medical purpose.10 For example, after 2009, 
we faced stringent additional conditions of the Health Inspectorate, 
after a Dutch probiotic trial in adults with acute pancreatitis showed 
increased mortality in the intervention group.11 Here, we report our 
experience with another safety issue which has led to ceasing of 
probiotic administration in our level III NICU: product contamination 
and missing of labelled strains.
Since 2012, approximately 900 preterm infants were treated 
with routine probiotics for the prevention of NEC in our level III 
NICU of the Erasmus MC in Rotterdam. According to local proto‐
col, we treated all infants with a gestational age below 32 weeks or 
birthweight below 1500 grams starting from day one.12 We used 
Infloran® 250 mg capsules, containing a combination of 109 CFU 
Lactobacillus acidophilus and 109 CFU Bifidobacterium bifidum (SIT 
Laboratorio Farmaceutico, Mede, Italy), which had shown NEC re‐
duction in a double‐blind trial.13 We strictly followed all storage and 
handling procedures. During the treatment period, we observed a 
significant decline in the incidence of NEC from 7.8% to 5.1% (OR 
0.63 (95% CI 0.42‐0.93), P = .02). The NEC reduction was not signifi‐
cantly associated with the introduction of probiotics after adjust‐
ment for potential confounders including the interaction with type 
of feeding (only breast milk, mixed or only formula) and the underly‐
ing downtrend in NEC incidence.12 Because of increasing concerns 
on the quality and safety of probiotics products used in clinical prac‐
tice, we did routine quality checks on the product content.
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Probiotics are effective in reducing necrotising enterocolitis in preterm infants, but 
routine use is not generally adopted. We describe a safety issue concerning contami‐
nation by pathogenic bacteria and missing of labelled strains in a probiotic product 
widely used in neonatal care. We recommend all centres using probiotics in the care 
of vulnerable patients to consider product safety checks in addition to the quality 
reports of manufacturers. Meanwhile, clinicians and manufacturers should collabo‐
rate to define quality standards for probiotic products in clinical settings as long as 
specific international regulations are lacking.
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We tested 15 capsules from five different strips, originating 
from three different lots. The expiry dates ranged from 3‐13 months 
after testing. To detect both aerobic and anaerobic bacteria, fungi 
and yeasts, we cultured the content on 4 different agar plates for 
5 days, according to the following procedures. The full content 
of probiotic powder of each tested capsule was dissolved in 1 mL 
BHI broth with Vitamin B6. Then, 10 μL was plated on TSA blood 
agar (BA), Chocolate agar (CHOC), Mac Conkey agar (McC) and 
Hemin and Vitamin K1 enriched Brucella Blood Agar plate (BBA).14 
Simultaneously, sterility control of the BHI‐VitB6 was set. The BA, 
CHOC and McC were incubated for 5 days at 35°C and 5% CO2, 
and the BBA was incubated 5 days anaerobically at 35°C. All grown 
bacteria were identified by MALDI‐TOF (Bruker). In only 1 lot pur‐
chased, both labelled probiotic microorganisms were detectable in 
all capsules. In the other two lots, one or both strains were miss‐
ing and varying contamination was found, with Streptococcus oralis, 
Lactococcus garvieae, Enterococcus feacalis, Enterococcus faecium and 
Lactococcus lactis (Table 1).
The level III NICU of the Emma Children's Hospital in Amsterdam 
was about to start with probiotics in preterm infants and inde‐
pendently purchased the same product. As they also found contam‐
ination with S oralis in lot 4583A, we consider contamination after 
purchase highly unlikely.
Unfortunately, we were not able to perform additional valida‐
tion or quantitative PCR, because the disapproved lots were directly 
returned to the manufacturer according to hospital regulations. By 
plating 1/100 of dissolved full capsules (that are supposed to con‐
tain 109 CFU of each labelled probiotic microorganisms), one would 
ideally expect to culture 107 CFUs of each probiotic strain. Based 
on this estimated detection level, we can assume that the capsules 
without detectable probiotics contained <100 CFU per capsule.
Even without knowing the exact quantity of contaminants, we 
question the safety of the contaminated products. The possible clin‐
ical consequences of a contaminated probiotic product have dramat‐
ically been shown in 2014, by a fatal gastrointestinal mucormycosis 
in a preterm infant.15 We could only find two other reports on con‐
taminated products as a cause of infant sepsis, of whom both have 
recovered well.16,17 Pathogenicity of the contaminating microorgan‐
isms is difficult to rule out in preterm infants whose gastrointestinal 
barrier function and immune system are still compromised. Even 
apparently commensal skin and gastrointestinal bacteria frequently 
cause sepsis in very preterm infants.18,19 We detected L lactis, which 
may be harmless as natural exposure is likely common for its wide‐
spread use in cheese industry without reports on pathogenicity.20 
L garviae is associated with outbreaks of infections in fish. It is a rare 
cause of infective endocarditis in adults with valvular disease after 
ingestion of raw seafood, with no reports on infection in children.21 
The human commensals Streptococcus oralis (including Streptococcus 
pneumoniae) and Enterococcus feacalis and faecium are likely of most 
concern, as these can cause neonatal sepsis in preterm infants.18
The tested probiotic product is produced according to general 
European drug regulations that lack special regulations for pro‐
biotic products.22 In accordance to this and other international 
Pharmacopeas, microbiological quality of ‘non‐sterile drugs’ is deemed 
acceptable if Escherichia coli, Staphylococcus aureus and Salmonella 
species are absent, and if total counts of bile‐tolerant Gram‐negative 
bacteria, aerobic microbes and yeast or moulds are below predefined 
levels of colony forming units (CFU) per gram or mL.23,24 We sug‐
gest that these regulations may not be strict enough when it comes 
to safety of probiotic use in preterm infants and that redefinition of 
so‐called ‘objectionable organisms’ for this vulnerable population is 
needed. From a clinical point of view, an ideal product would contain 
only the labelled probiotic strains, in an acceptable quantity during 
shelf life with no contamination of any other microorganism at all.
In response to our report, the manufacturer retested the prod‐
ucts and confirmed contamination of lot 4583A and 5145A (personal 
communication). They did not report on the presence or absence of 
the labelled probiotic strains in the product. As the product was still 
considered safe according to the regulations, no recall action was 
taken by the manufacturer. Of the three lots tested, we only used 
the uncontaminated lot (4307B) in patient care. When products with 
missing strains have been administered earlier, this may have been 
for no benefit and may explain the lack of effect on NEC in our time‐
series analyses.12 We have stopped administration of probiotics in 
our unit until we receive products that pass our own safety and vi‐
ability checks.
This report has several limitations, as it is just a description of our 
local clinical findings on a single product, and not part of a prospec‐
tive quality control project. In retrospect, we should have quantified 
the contaminants by plate count or qPCR. Considering the sensitive 
methods used, bacterial enumeration of the contaminants may have 
been low, which can limit the clinical relevance. Next, additional test‐
ing for non‐viable probiotic bacteria could have helped to differenti‐
ate between issues in the production process versus limited viability 
during shelf life. However, the product label claims live probiotics, by 
declaring the quantitative amount as CFU per capsule. Viability and 
purity testing would ideally be done along the chain, from production, 
storage and shipping to the hospital, pharmacy and patient ward, to 
TA B L E  1   Microorganisms identified in capsules with label 
claiming Lactobacillus acidophilus and Bifidobacterium bifidum, by 
MALDI‐TOF. Shown are percentages of capsules of the specified lot 
tested positive for mentioned microorganism
Lot 4307B 4583A 5145A
Capsules tested N = 4 N = 4 N = 7
Label claimed
Lactobacillus acidophilus 100% 100% 0%
Bifidobacterium bifidum 100% 75% 0%
Contaminants
Streptococcus oralis – 100% –
Lactococcus garvieae – – 100%
Enterococcus feacalis – – 57%
Enterococcus faecium – – 43%
Lactococcus lactis – – 29%
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reveal critical steps in the process. However, we consider quality con‐
trol the responsibility of the manufacturer and regulatory agencies 
and we lack funding to study this in more detail. How our findings 
relate to other products and other settings are unclear. Of note, we 
have no data on the product widely used in Germany, with the same 
brand name but different content (Bifidobacterium infantis instead 
of Bifidobacterium bifidum) or on any other products. However, our 
findings are not unique. Earlier reports have shown that mismatches 
between the content and the label claims are common in commercial 
probiotic products. Reported composition mismatches included in‐
correct taxonomy, presence of un‐labelled species or missing of the 
labelled (sub) species. Similar to our findings, these content biases 
were found with pill‐to‐pill (within a lot) and lot‐to‐lot variation.25,26 
Another possible shortcoming is that we have no access to detailed 
quality control findings of the manufacturer. The main strengths of 
this report include our methods to detect a wide range of potential 
contaminants. Methods were based on international standards with 
additional state‐of‐the‐art culture and detection procedures, run in 
a ISO 15189 certified laboratory. The contamination by S oralis was 
confirmed by an independent laboratory, and the positive findings 
in the first lot indicate sufficient sensitivity to detect the probiotics.
We aim to call attention to probiotic product quality, as these 
can threat patient safety in at‐risk populations, but may also lead 
to bias and misinterpretation of clinical trial results. This underlines 
the need for independent quality control, and for rapid and accu‐
rate molecular techniques for identification of (sub) species, such as 
quantitative real‐time PCR, flow cytometry and MALDI‐TOF Mass 
Spectrometry.24,27 However, also by simple culture techniques, con‐
tamination of products may be found.
In conclusion, despite the mass of current literature showing that 
probiotics can prevent NEC and save many lives, general adoption of 
probiotic use is hampered by different issues. This report illustrates 
that quality issues of the products currently available are one of them. 
We are reluctant to withhold patients a highly effective treatment, 
but we are also worried about the potential risks of impure products. 
We understand that quality control of unsterile products is complex 
and that 100% pure products are difficult to guarantee. As long as 
regulatory requirements may not be strict enough, we recommend all 
centres using probiotics in the care of vulnerable patients to consider 
routine bacterial checks in addition to quality checks of manufactur‐
ers to guarantee product safety. The same warning holds true for on‐
going and future clinical trials. Meanwhile, clinicians, microbiologists 
and manufacturers should collaborate to define population‐specific 
quality standards for probiotic products in clinical settings as long as 
specific international regulations are lacking for at‐risk populations.
CONFLIC T OF INTERE S T
None of the authors have anything to disclose regarding poten‐
tial/perceived conflicts of interest or financial ties to products in 
the study. MJV is unpaid Scientific Advisory Board member of 
Neobiomics (www.neobi omics.eu).
ORCID
Marijn J. Vermeulen  https://orcid.org/0000‐0001‐9686‐8186 
R E FE R E N C E S
 1. Patel RM, Underwood MA. Probiotics and necrotizing enterocolitis. 
Semin Pediatr Surg. 2018;27:39‐46.
 2. Viswanathan S, Lau C, Akbari H, Hoyen C, Walsh MC. Survey 
and evidence based review of probiotics used in very low birth 
weight preterm infants within the United States. J Perinatol. 
2016;36:1106‐1111.
 3. Denkel LA, Schwab F, Garten L, Geffers C, Gastmeier P, Piening B. 
Protective effect of dual‐strain probiotics in preterm infants: a multi‐
center time series analysis. PLoS ONE. 2016;11:e0158136.
 4. van den Akker CHP, van Goudoever JB, Szajewska H, et al. Probiotics 
for preterm infants: a strain specific systematic review and network 
meta‐analysis. J Pediatr Gastroenterol Nutr. 2018;67(1):103‐122.
 5. Bafeta A, Koh M, Riveros C, Ravaud P. Harms reporting in random‐
ized controlled trials of interventions aimed at modifying microbi‐
ota: a systematic review. Ann Intern Med. 2018;169:240‐247.
 6. Costa RL, Moreira J, Lorenzo A, Lamas CC. Infectious complica‐
tions following probiotic ingestion: a potentially underestimated 
problem? A systematic review of reports and case series. BMC 
Complement Altern Med. 2018;18:329.
 7. Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacte‐
remia during probiotic treatment of short gut syndrome. J Pediatr 
Gastroenterol Nutr. 2004;38:457‐458.
 8. Ohishi A, Takahashi S, Ito Y, et al. Bifidobacterium septicemia asso‐
ciated with postoperative probiotic therapy in a neonate with om‐
phalocele. J Pediatr. 2010;156:679‐681.
 9. Esaiassen E, Cavanagh P, Hjerde E, Simonsen GS, Stoen R, 
Klingenberg C. Bifidobacterium longum Subspecies infantis 
Bacteremia in 3 extremely preterm infants receiving probiotics. 
Emerg Infect Dis. 2016;22:1664‐1666.
 10. Sanders ME, Merenstein DJ, Ouwehand AC, et al. Probiotic use in 
at‐risk populations. J Am Pharm Assoc. 2003;2016(56):680‐686.
 11. Besselink MGH, van Santvoort HC, Buskens E, et al. Probiotic pro‐
phylaxis in predicted severe acute pancreatitis: a randomised, dou‐
ble‐blind, placebo‐controlled trial. Lancet. 2008;371:651‐659.
 12. Samuels N, van de Graaf R, Been JV, et al. Necrotising enterocolitis 
and mortality in preterm infants after introduction of probiotics: a 
quasi‐experimental study. Sci Rep. 2016;6:31643.
 13. Lin HC, Hsu CH, Chen HL, et al. Oral probiotics prevent necrotizing 
enterocolitis in very low birth weight preterm infants: a multicenter, 
randomized, controlled trial. Pediatrics. 2008;122:693‐700.
 14. Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry 
ML, Warnock DW. Manual of Clinical Microbiology, 10th edn. 
Washington, DC: American Society for Microbiology; 2011:1. ISBN 
978‐1‐55581‐463‐2.
 15. Vallabhaneni S, Walker TA, Lockhart SR, et al. Notes from the field: 
fatal gastrointestinal mucormycosis in a premature infant associ‐
ated with a contaminated dietary supplement–Connecticut, 2014. 
MMWR Morb Mortal Wkly Rep. 2015;64:155‐156.
 16. Barton LL, Rider ED, Coen RW. Bacteremic infection with 
Pediococcus: vancomycin‐resistant opportunist. Pediatrics. 
2001;107:775‐776.
 17. Brecht M, Garg A, Longstaff K, Cooper C, Andersen C. Lactobacillus 
sepsis following a laparotomy in a preterm infant: a note of caution. 
Neonatology. 2016;109:186‐189.
 18. Stoll BJ, Hansen N, Fanaroff AA, et al. Late‐onset sepsis in very 
low birth weight neonates: the experience of the NICHD Neonatal 
Research Network. Pediatrics. 2002;110:285‐291.
4  |     VERMEULEN Et aL.
 19. Downey LC, Smith PB, Benjamin DK Jr. Risk factors and preven‐
tion of late‐onset sepsis in premature infants. Early Hum Dev. 
2010;86(Suppl 1):7‐12.
 20. Song AA, In L, Lim S, Rahim RA. A review on Lactococcus lactis: from 
food to factory. Microb Cell Fact. 2017;16:55.
 21. Malek A, De la Hoz A, Gomez‐Villegas SI, Nowbakht C, Arias CA. 
Lactococcus garvieae, an unusual pathogen in infective endo‐
carditis: case report and review of the literature. BMC Infect Dis. 
2019;19:301.
 22. European Directorate for the Quality of Medicines. The European 
Pharmacopoeia: Microbiological quality of non‐sterile pharmaceu‐
tical preparations and substances for pharmaceutical use, 10th edn. 
Strasbourg, France: The European Pharmacopoeia; 2019:627‐628.
 23. World Health Organization. The International Pharmacopeia, 4th edn. 
S.3.7 ed2012.
 24. Jackson SA, Schoeni JL, Vegge C, et al. Improving end‐user trust 
in the quality of commercial probiotic products. Front Microbiol. 
2019;10:739.
 25. Lewis ZT, Shani G, Masarweh CF, et al. Validating bifidobacterial 
species and subspecies identity in commercial probiotic products. 
Pediatr Res. 2016;79:445‐452.
 26. Morovic W, Hibberd AA, Zabel B, Barrangou R, Stahl B. Genotyping 
by PCR and high‐throughput sequencing of commercial probiotic 
products reveals composition biases. Front Microbiol. 2016;7:1747.
 27. Angelakis E, Million M, Henry M, Raoult D. Rapid and accurate bac‐
terial identification in probiotics and yoghurts by MALDI‐TOF mass 
spectrometry. J Food Sci. 2011;76:M568‐M572.
How to cite this article: Vermeulen MJ, Luijendijk A, van 
Toledo L, van Kaam AH, Reiss IKM. Quality of probiotic 
products for preterm infants: Contamination and missing 
strains. Acta Paediatr. 2019;00:1–4. https ://doi.org/10.1111/
apa.14976 
